

Evidence dossier - Leon Cooperman

GetCoattail manager profile: <https://getcoattail.com/manager/leon-cooperman> | CIK 0000898382 | Rank #108 of 149 tracked managers by reported 13F value.

Background: Founded: 1991 | HQ: Boca Raton, Florida, U.S. | Style: Value-oriented long-short equity, fundamental stock analysis | Key person: Leon Cooperman

Background source: <https://www.highperformr.ai/company/omega-advisors>

1. Latest filing snapshot (as reported)

Period end: 2026-06-30 Filed: 2026-08-14 Reported total value: \$3.5B Positions: 39 Top-10 concentration: 68.4% of reported value.

Ticker	Company	Weight	Reported value
VRT	Vertiv Holdings Co	20.37%	\$722M
RKT	Rocket Cos Inc	9.33%	\$331M
ET	Energy Transfer Lp	7.18%	\$255M
PLGO	Pelagos Insurance Capital Lt	5.84%	\$207M
GPGI	Gpgi Inc	5.09%	\$180M
MP	Mp Materials Corp	4.74%	\$168M
APO	Apollo Global Management Inc	4.46%	\$158M
MIR	Mirion Technologies Inc	4.24%	\$150M
OMF	Onemain Holdings Inc	3.66%	\$130M
ASH	Ashland Inc	3.52%	\$125M

2. Hypothetical 13F-clone results

Window: 2019-05-15 to 2026-10-02 (25 filings). Cumulative: +125.3% CAGR: +11.63% SPY same window: cumulative +201.2%, CAGR +16.11%. Trailing CAGR - 10Y: n/a, 5Y: +11.34%, 3Y: +16.68%, 1Y: +4.18%. Max drawdown (month-end, approximate): -35.0%.

Method (summary): For each Form 13F filing in the history table, the clone takes the positions and weights exactly as disclosed (reported values at the period end). From the filing date until the next filing date, each position earns the return of its dividend-adjusted closing price (Yahoo Finance daily bars; split- and dividend-adjusted). At each new filing the clone rebalances to the newly disclosed weights. Positions that cannot be priced (non-U.S. listings, some recent IPOs and delisted names) are excluded from both the weights and the returns, and the covered share of reported value is stated in this dossier. The benchmark is SPY on the same dividend-adjusted basis over the identical window. Month-end values are used for drawdown and trailing-window statistics and are approximate.

3. Filing history - every clone input

Each row is one SEC Form 13F filing used by the clone. Accession numbers link to the filing index at sec.gov: <https://www.sec.gov/Archives/edgar/data/<CIK>/<accession without dashes>/<accession>-index.htm>

Quarter	Accession no.	Filed	CUSIPs
2019Q1	0001567619-19-010983	2019-05-15	55
2019Q2	0001567619-19-016679	2019-08-14	58
2019Q3	0001567619-19-021314	2019-11-14	61
2019Q4	0001567619-20-003586	2020-02-14	60
2020Q1	0001567619-20-010306	2020-05-15	43
2020Q2	0001567619-20-015244	2020-08-14	40
2020Q3	0001567619-20-019712	2020-11-16	41

2020Q4	0001567619-21-003770	2021-02-16	46
2021Q1	0001567619-21-010304	2021-05-17	55
2021Q2	0001567619-21-015661	2021-08-16	67
2021Q3	0001567619-21-020244	2021-11-15	65
2021Q4	0001567619-22-003846	2022-02-14	56
2023Q2	0000945621-23-000457	2023-08-30	54
2023Q3	0000945621-23-000579	2023-11-14	54
2023Q4	0000945621-24-000256	2024-02-14	50
2024Q1	0000945621-24-000434	2024-05-15	51
2024Q2	0000945621-24-000673	2024-08-14	52
2024Q3	0000945621-24-000945	2024-11-14	40
2024Q4	0000945621-25-000191	2025-02-14	45
2025Q1	0000945621-25-000506	2025-05-15	41
2025Q2	0000945621-25-000771	2025-08-14	40
2025Q3	0000945621-25-001130	2025-11-14	41
2025Q4	0000945621-26-000329	2026-02-17	40
2026Q1	0000945621-26-000719	2026-05-15	41
2026Q2	0000945621-26-001056	2026-08-14	39

4. Coverage and adjustments

Price coverage at the latest filing: 97.9% of reported value is covered by our price history and included in the clone; the rest is excluded (mostly non-U.S. listings, recent IPOs, delisted names).

5. Disclaimer

This document and the associated web profile present a hypothetical replication ("13F clone") of the long U.S. equity positions disclosed on Form 13F. It is not the named fund's actual investment return: Form 13F excludes short positions, bonds, cash, non-U.S. listings, private holdings, leverage and fees, and positions are only observable quarterly, with a filing lag of up to 45 days. Nothing here is investment advice or a recommendation. Past hypothetical performance does not guarantee future results.